Literature DB >> 18477217

DEK overexpression in uterine cervical cancers.

Qunying Wu1, Zhuhu Li, Hai Lin, Longzhe Han, Shuangping Liu, Zhenhua Lin.   

Abstract

The purpose of the present paper was to investigate the significance of DEK protein expression in uterine cervical lesions and its relationship with HPV infection status. DEK protein expression was studied in 253 cervical lesions, including 30 non-neoplastic cervix with or without squamous metaplasia, 64 cervical intra-epithelial neoplasias (CIN; CIN-1, n = 28; CIN-2, n = 17; CIN-3, n = 19), 102 squamous cell carcinomas (SCC), 51 adenocarcinomas, and six adenosquamous cell carcinomas (adenoSCC) on immunohistochemistry. For comparison, HPV-positive and -negative cervical cancer cell lines were also included. The HPV screening was performed using TaKaRa polymerase chain reaction. On immunohistochemistry DEK was found to be negative in all 30 non-neoplastic cervical epithelia, but it was positive in 96.1% of SCC (98/102), 92.2% of adenocarcinomas (47/51), 100% of adenoSCC (6/6), 85.7% of CIN-1 (24/28), 94.1% of CIN-2 (16/17), and 89.5% of CIN-3 (17/19). There was no significant difference between HPV-positive and -negative cervical lesions. Also, strongly positive staining was observed in all aforementioned cervical cancer cell lines regardless of HPV infection, according to immunocytochemistry. In summary, DEK plays an important role in the carcinogenesis of cervical cancers, and can be helpful for early diagnosis, and is a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18477217     DOI: 10.1111/j.1440-1827.2008.02239.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  21 in total

Review 1.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 2.  Embryonic stem cell-specific signature in cervical cancer.

Authors:  Jorge Organista-Nava; Yazmín Gómez-Gómez; Patricio Gariglio
Journal:  Tumour Biol       Date:  2013-10-28

3.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

4.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

5.  TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Authors:  Sounak Gupta; Sarah H Johnson; George Vasmatzis; Binu Porath; Jeannette G Rustin; Priya Rao; Brian A Costello; Bradley C Leibovich; R Houston Thompson; John C Cheville; William R Sukov
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

6.  Future directions and treatment strategies for head and neck squamous cell carcinomas.

Authors:  Trisha M Wise-Draper; David J Draper; J Silvio Gutkind; Alfredo A Molinolo; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  Transl Res       Date:  2012-02-28       Impact factor: 7.012

7.  Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.

Authors:  Yingfu Ou; Rongjun Xia; Fanyong Kong; Xiaokang Zhang; Shengjin Yu; Lili Jiang; Linlin Zheng; Lijuan Lin
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

8.  Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.

Authors:  Trisha M Wise-Draper; Rachael A Mintz-Cole; Teresa A Morris; David S Simpson; Kathryn A Wikenheiser-Brokamp; Mark A Currier; Timothy P Cripe; Gerard C Grosveld; Susanne I Wells
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

9.  DEK proto-oncogene expression interferes with the normal epithelial differentiation program.

Authors:  Trisha M Wise-Draper; Richard J Morreale; Teresa A Morris; Rachael A Mintz-Cole; Elizabeth E Hoskins; Scott J Balsitis; Nader Husseinzadeh; David P Witte; Kathryn A Wikenheiser-Brokamp; Paul F Lambert; Susanne I Wells
Journal:  Am J Pathol       Date:  2008-11-26       Impact factor: 4.307

10.  Melanoma proliferation and chemoresistance controlled by the DEK oncogene.

Authors:  Michael S Khodadoust; Monique Verhaegen; Ferdinand Kappes; Erica Riveiro-Falkenbach; Juan C Cigudosa; David S L Kim; Arul M Chinnaiyan; David M Markovitz; María S Soengas
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.